Celgene Stock

CELG

Delayed Nasdaq Other stock markets 08:00:00 21/11/19 am AEDT			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

15/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

07/04/21	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
25/03/21	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
02/02/21	BX Swiss AG startet Handel in neuem Bondsegment
07/07/20	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
03/07/20	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 67.38B 62.15B 57.4B 109B 7,347B 111B 743B 292B 3,619B 289B 283B 12,443B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 79.82B 73.63B 68B 129B 8,704B 131B 880B 345B 4,288B 343B 335B 14,740B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

15/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
22/06/21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
23/02/21	Celgene Corporation Issues Notice of Redemption of Notes	CI
04/02/21	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
05/01/21	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
23/12/20	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
06/11/20	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
23/09/20	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
22/09/20	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
26/03/20	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
11/03/20	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
05/03/20	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

28/02/23	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
25/08/22	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/07/22	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
25/02/22	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
05/08/21	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.37B 10.49B 9.69B 18.39B 1,240B 18.69B 125B 49.22B 611B 48.82B 47.76B 2,100B	15.28B 13.37B 12.33B 11.39B 21.61B 1,457B 21.97B 147B 57.85B 718B 57.38B 56.13B 2,468B
Net income	2.94B 2.57B 2.37B 2.19B 4.16B 280B 4.23B 28.34B 11.13B 138B 11.04B 10.8B 475B	4.05B 3.54B 3.26B 3.01B 5.72B 386B 5.82B 39B 15.32B 190B 15.19B 14.86B 654B
Net Debt	3.79B 3.32B 3.06B 2.83B 5.36B 362B 5.45B 36.56B 14.36B 178B 14.24B 13.93B 613B	14.22B 12.44B 11.47B 10.6B 20.11B 1,356B 20.45B 137B 53.84B 668B 53.4B 52.23B 2,297B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile